AlphAIAlphAI — Financial news for AI agents
yahoo.comSEP 83 min read$CRSP

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

Original reporting
yahoo.com
Published Sep 8, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Why CRISPR Therapeutics Stock Rocked the Market Last Month — source image
Source · yahoo.com
Decision brief

The 30-second read

$CRSPBullishMed
01

Why it matters

Earnings beat and regulatory news may trigger a short‑term rally, but long‑term valuation depends on pipeline execution.

02

Market read

First‑hand earnings and FDA news provide fresh material for traders targeting biotech momentum.

03

What to watch

Unidentified $10M upfront payment source and future partnership pipeline.

Relevance 8/10Novelty 8/10Timing: early August (Q2 release)

Background

CRISPR Therapeutics reported Q2 results and FDA label expansion for its approved product Casgevy.

Company-level read

Ticker impact

$CRSPBullishHigh confidence
Context

Q2 earnings released Aug 3 with revenue $10.2M, net loss $91.5M and FDA label expansion for Casgevy.

Expected impact

upward pressure in pre‑market trading

Evidence & confidence

Revenue topped analyst forecasts and a new pediatric indication adds growth potential.

Market effects

Sector

Strengthens outlook for gene‑editing biotech sector.

Regional

Positive for US biotech investors.

Global

Highlights FDA's expanding role in gene‑therapy approvals.

Counterpoint

What could challenge this read

Revenue still modest; loss remains high, risk of cash burn persists.

Key entities

  • company
    CRISPR Therapeutics

    Gene‑editing biotech (NASDAQ: CRSP).

  • partner
    Vertex Pharmaceuticals

    Co‑developer and marketer of Casgevy.

Read at source← All news

Related articles

SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min
AUG 28
$CRSPMedAI 8/10

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP) presented Phase 1a data for CTX310® at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose. The therapy was well tolerated with no serious adverse events. Data was also published in The New England Journal of Medicine. The company is advancing CTX310 in a Phase 1b trial and expects to provide an update in the second half of 2026.

globenewswire.com2 min
AUG 4
$CRSPMed

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.

zacks.com6 min
AUG 3
$CRSPMed

CRISPR Therapeutics reports $91.2 million second quarter net loss

CRISPR Therapeutics (CRSP) reported Q2 2026 total revenue of $10.2M and a net loss of $91.2M for the quarter ended June 30. Cash, cash equivalents and marketable securities were $2.36B vs $1.98B at end-2025. CASGEVY revenue was $76M, up 78% QoQ and 151% YoY. The company cited FDA approval for children as young as 2 and began Phase 1 trials for CTX340 and CTX460.

quiverquant.com4 min